Mylan Launches Rs 3,481-Crore Block Deal to Exit Biocon

Mylan, a subsidiary of the global pharmaceutical giant Viatris, has initiated a significant block deal to sell its entire stake in the Indian biotechnology firm Biocon. The transaction involves approximately 92 million shares, which accounts for 5.64% of Biocon’s total outstanding equity. Valued at roughly Rs 3,481 crore, or $363 million, the sale signals a major structural shift in the long-standing partnership between the two entities.

The shares are being offered to investors at a 7.9% discount relative to Biocon's most recent closing price, suggesting an effort by Mylan to ensure a swift and complete exit from the Indian entity. The secondary sale is strictly an investor-to-investor transaction and will result in no direct capital inflow for Biocon. Citigroup Global Markets India and Jefferies India are serving as the book-running managers for this substantial divestment.

The announcement has put Biocon shares in sharp focus as market participants adjust to the departure of a key stakeholder. While the sale does not alter the underlying business operations of Biocon, the large volume of stock hitting the market is expected to create temporary volatility in its share price. Investors remain cautious as the market absorbs this supply, while long-term observers evaluate the implications of Mylan’s exit on Biocon’s future strategic focus and partnership landscape.